Platinum

If you have ever received cisplatin or carboplatin chemotherapy, or worked with platinum in an industrial setting, this test answers a specific question: how much platinum is your body still carrying, and how fast are you clearing it out? The answer can be surprising. Studies of testicular cancer survivors have detected platinum in urine up to 40 years after their last cisplatin infusion. Estimated half-lives vary substantially across studies and modeling approaches, ranging from roughly 0.4 to 2 years in earlier urinary excretion work, about 3.7 years for serum platinum, and up to about 9.8 years in more recent long-term urinary modeling.

This is a research and monitoring test, not a routine health check. It does not have standardized clinical cutpoints for the general population, and a single reading cannot tell you whether platinum is harming your kidneys. Its value comes from tracking exposure and clearance over time, especially in people who have been through platinum-based chemotherapy or who work in industries where platinum dust is present.

What This Test Actually Reflects

Unlike most biomarkers, platinum is not something your body makes. Every atom of platinum in your urine came from outside the body, either from a platinum-containing chemotherapy drug (like cisplatin, carboplatin, or oxaliplatin) or from environmental or occupational exposure. The kidneys filter it out of the blood, so what shows up in a 24-hour urine collection reflects two things: how much platinum you have been exposed to, and how efficiently your kidneys are moving it out.

The 24-hour collection matters here. A single spot sample can miss the true daily excretion because platinum output varies with hydration, timing after exposure, and kidney flow. Collecting all urine over a full day averages out those swings and gives a cleaner picture of your total daily platinum load.

Chemotherapy Monitoring

The clearest use case is people who have received cisplatin or carboplatin. Cisplatin is heavily excreted through urine, so urinary platinum after a dose reflects how the kidneys are handling the drug. In one study of 13 adults receiving cisplatin at 30 to 75 mg per square meter of body surface, peak urinary platinum in the first two hours after infusion correlated strongly with tubular injury signals measured 10 days later, including KIM-1, NGAL (a marker released when kidney tubule cells are stressed), clusterin, and cystatin C.

That said, urine platinum at 24 hours is a limited stand-alone marker of acute kidney injury. In a study of 115 children treated with cisplatin at 12 Canadian centers, higher urine platinum tracked with higher cisplatin dose and younger age, but it was not associated with clinically defined acute kidney injury or with KIM-1. The link to NGAL was weak. The takeaway: urinary platinum tells you about drug exposure and possibly mild tubular stress, but it cannot replace kidney function tests for diagnosing injury.

Long-Term Retention After Treatment

Platinum leaves the body far more slowly than most people expect. In testicular cancer survivors treated with cisplatin, the median urine platinum concentration was 376 pg per milliliter, and researchers estimated a urine half-life of about 9.8 years. Some survivors had measurable platinum up to 40 years after their last infusion. Earlier studies reported urinary platinum tens to thousands of times higher than in unexposed people years after cisplatin therapy, with reported ratios spanning roughly 40 times higher at 8 years post-treatment to 100–1,000 times higher across 5 to 17 years and mean group levels around 2,700 times higher in one cohort.

This matters because it means a single elevated result decades after treatment is expected, not alarming. What it does not tell you is whether the retained platinum is causing ongoing harm. Standard lab methods measure total platinum, which includes both the original drug and its breakdown products, and cannot distinguish biologically active forms from inert ones.

Occupational and Environmental Exposure

Platinum industry workers can carry a substantial internal dose. In one study of refinery workers, post-shift urinary platinum reached 6,270 ng per gram of creatinine, roughly 1,000 times the median in unexposed people. Excretion peaked about 10 hours after inhalation exposure, with an initial elimination half-life of about 50 hours. A portion of the incorporated platinum appeared to be stored longer in the body.

Dermal absorption also matters. Refinery workers had urinary platinum concentrations from below 0.1 to 3 micrograms per gram of creatinine, and urine levels correlated with both respiratory and skin exposure. Even in hospital settings, urinary platinum has been detected in personnel handling platinum-containing drugs, although modern operating rooms with proper safety measures often show levels below the detection limit.

Why a Single Reading Cannot Diagnose Kidney Injury

It is tempting to interpret a high urinary platinum result as evidence of kidney damage. The evidence does not support that leap. Conventional kidney markers like serum creatinine and the urine albumin-to-creatinine ratio have given inconsistent results in platinum-related nephrotoxicity studies. Newer urinary markers, specifically cystatin C, KIM-1, and clusterin, rose significantly in cisplatin-treated patients who developed kidney trouble and appear more sensitive for early tubular injury than platinum itself.

In practical terms: if you are on or recently completed platinum chemotherapy and want to assess kidney impact, urinary platinum alone is not enough. Pairing it with cystatin C, eGFR, and urinary tubular injury markers gives a more complete picture.

When Results Can Be Misleading

• Recent platinum drug exposure: cisplatin, carboplatin, or oxaliplatin infusion in the days before collection can raise urinary platinum by orders of magnitude. Refinery workers saw excretion peak about 10 hours after inhalation, with an initial half-life around 50 hours.
• Incomplete 24-hour collection: missing even a single urination during the collection window can make results falsely low. The full sample must be captured from the first morning void through the same time the next day.
• Kidney function shifts: in oxaliplatin-treated adults, moderate and severe renal impairment increased the exposure (AUC) of unbound platinum by about 95% and 342%, respectively, and reduced how efficiently the kidneys eliminated it. A low urinary result in someone with reduced kidney function may reflect impaired clearance, not low exposure.
• Timing of concomitant chemotherapy drugs: in a pharmacokinetic model of cisplatin-treated patients, those receiving ondansetron had about 331% higher circulating unbound platinum exposure than those receiving palonosetron, which can shift the amount available for urinary excretion.

Tracking Your Trend

Because 24-hour urine platinum has no standardized clinical cutpoint for the general population, a single number in isolation has limited meaning. The value of this test comes from watching how your levels change over time. For someone recovering from platinum chemotherapy, serial measurements can show whether platinum is slowly clearing (as expected, given the multi-year half-life) or whether excretion has plateaued. For workers with ongoing occupational exposure, trending shows whether safety measures are keeping internal dose in check.

A reasonable cadence: get a baseline, then repeat every 6 to 12 months if you are actively monitoring exposure or long-term retention. If a specific event changes your risk (new job, hospital handling of platinum drugs, or a treatment cycle), retest sooner to capture the shift.

Decision Pathway for Unexpected Results

An out-of-pattern urinary platinum result is a starting point for investigation, not a diagnosis. If your level is unexpectedly high and you have a history of platinum chemotherapy, the finding is likely reflecting long-term retention rather than a new problem. Pair it with cystatin C and an eGFR calculation to assess kidney function, and consider urinary KIM-1 or NGAL if you or your oncologist want to look for tubular stress.

If you have no chemotherapy history and levels are elevated, occupational or environmental exposure is the leading suspect. Investigation should focus on identifying the source: workplace air, dust, or dermal contact. Referral to an occupational medicine specialist or clinical toxicologist is appropriate. If elevated levels persist despite reducing exposure, that pattern warrants deeper workup and monitoring of kidney function over time.